company background image
GNFT logo

Genfit ENXTPA:GNFT Stock Report

Last Price

€3.46

Market Cap

€172.5m

7D

-1.8%

1Y

-1.0%

Updated

22 Dec, 2024

Data

Company Financials +

Genfit S.A.

ENXTPA:GNFT Stock Report

Market Cap: €172.5m

GNFT Stock Overview

A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. More details

GNFT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Rewards

Price-To-Earnings ratio (7.7x) is below the French market (13.8x)

Earnings are forecast to grow 41.21% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Volatile share price over the past 3 months compared to the French market


My Notes

Capture your thoughts, links and company narrative

Genfit S.A. Competitors

OSE Immunotherapeutics

ENXTPA:OSE

€153.6m

Eurobio Scientific Société anonyme

ENXTPA:ALERS

€254.1m

genOway Société anonyme

ENXTPA:ALGEN

€34.5m

PCAS

ENXTPA:PCA

€109.9m

Price History & Performance

Summary of share price highs, lows and changes for Genfit
Historical stock prices
Current Share Price€3.46
52 Week High€5.86
52 Week Low€3.03
Beta1.1
1 Month Change-14.78%
3 Month Change-24.70%
1 Year Change-1.00%
3 Year Change-24.39%
5 Year Change-80.97%
Change since IPO-73.30%

Recent News & Updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Nov 16
Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27
We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 26
Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Nov 16
Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27
We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 26
Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Sep 24
Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Sep 22
Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23
Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Jan 03
Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

Sep 22
Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Jul 05
Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Jun 23
Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Dec 28
We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30
New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29
Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14
Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28
Is Genfit (EPA:GNFT) A Risky Investment?

Shareholder Returns

GNFTFR BiotechsFR Market
7D-1.8%-2.5%-1.7%
1Y-1.0%-30.5%-4.8%

Return vs Industry: GNFT exceeded the French Biotechs industry which returned -30.5% over the past year.

Return vs Market: GNFT exceeded the French Market which returned -4.8% over the past year.

Price Volatility

Is GNFT's price volatile compared to industry and market?
GNFT volatility
GNFT Average Weekly Movement8.1%
Biotechs Industry Average Movement7.1%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.7%
10% least volatile stocks in FR Market2.3%

Stable Share Price: GNFT's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: GNFT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
1999169M. Prigentwww.genfit.com

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

Genfit S.A. Fundamentals Summary

How do Genfit's earnings and revenue compare to its market cap?
GNFT fundamental statistics
Market cap€172.52m
Earnings (TTM)€22.27m
Revenue (TTM)€80.47m

7.7x

P/E Ratio

2.1x

P/S Ratio

Is GNFT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNFT income statement (TTM)
Revenue€80.47m
Cost of Revenue€0
Gross Profit€80.47m
Other Expenses€58.20m
Earnings€22.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.45
Gross Margin100.00%
Net Profit Margin27.67%
Debt/Equity Ratio63.9%

How did GNFT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genfit S.A. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Jean-Jacques Le FurBryan Garnier & Co
Arnaud CadartCIC Market Solutions (ESN)